{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:19:42Z","timestamp":1791994782873,"version":"4.4.0"},"reference-count":63,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Introduction: The prognosis of chronic myeloid leukemia (CML) patients has been dramatically improved with the introduction of imatinib (IM), the first tyrosine kinase inhibitor (TKI). TKI resistance is a serious problem in IM-based therapy. The human S-phase kinase-associated protein 2 (SKP2) gene may play an essential role in the genesis and progression of CML. Aim of the study: We try to explore the diagnostic\/prognostic impact of SKP2 gene expression to predict treatment response in first-line IM-treated CML patients at an early response stage. Patients and methods: The gene expression and protein levels of SKP2 were determined using quantitative RT-PCR and ELISA in 100 newly diagnosed CML patients and 100 healthy subjects. Results: SKP2 gene expression and SKP2 protein levels were significantly upregulated in CML patients compared to the control group. The receiver operating characteristic (ROC) analysis for the SKP2 gene expression level, which that differentiated the CML patients from the healthy subjects, yielded a sensitivity of 86.0% and a specificity of 82.0%, with an area under the curve (AUC) of 0.958 (p &lt; 0.001). The ROC analysis for the SKP2 gene expression level, which differentiated optimally from the warning\/failure responses, yielded a sensitivity of 70.59% and a specificity of 71.21%, with an AUC of 0.815 (p &lt; 0.001). Conclusion: The SKP2 gene could be an additional diagnostic and an independent prognostic marker for predicting treatment responses in first-line IM-treated CML patients at an early time point (3 months).<\/jats:p>","DOI":"10.3390\/genes13060948","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:50:22Z","timestamp":1653555022000},"page":"948","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"13","author":[{"given":"Hossam","family":"Hodeib","sequence":"first","affiliation":[{"name":"Clinical Pathology Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Abd EL Hai","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-0535","authenticated-orcid":false,"given":"Mohamed A.","family":"Tawfik","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzahraa A.","family":"Allam","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed F.","family":"Selim","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-0188","authenticated-orcid":false,"given":"Mohamed E.","family":"Sarhan","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Selim","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-3422","authenticated-orcid":false,"given":"Nesreen M.","family":"Sabry","sequence":"additional","affiliation":[{"name":"Clinical Oncology Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Mansour","sequence":"additional","affiliation":[{"name":"Clinical Oncology Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Youssef","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Tanta University, Tanta 31527, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2019 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Antolini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: Mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gunby","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: Reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"Eide","year":"2007","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3324\/haematol.2010.039560","article-title":"Mutant BCR-ABL clones in chronic myeloid leukemia","volume":"96","author":"Mathisen","year":"2011","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosomepositive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer, J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/cdd.2016.53","article-title":"Regulation of pluripotency and differentiation by deubiquitinating enzymes","volume":"23","author":"Suresh","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/ERC-14-0516","article-title":"Deubiquitinases and the new therapeutic opportunities offered to cancer","volume":"22","author":"Pfoh","year":"2015","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/iub.1402","article-title":"Deubiquitinating enzymes in cellular signaling and disease regulation","volume":"67","author":"Hanpude","year":"2015","journal-title":"IUBMB Life"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/OTT.S125789","article-title":"Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel","volume":"10","author":"Huang","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood.V100.8.2950","article-title":"Expression of Skp2, a p27 (Kip1) ubiquitin ligase, in malignant lymphoma: Correlation with p27 (Kip1) and proliferation index","volume":"100","author":"Lim","year":"2002","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5732\/cjc.011.10319","article-title":"Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis","volume":"31","author":"Wang","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1080\/15384101.2016.1160986","article-title":"Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation","volume":"15","author":"Zhang","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1089\/dna.2017.3886","article-title":"miR-1297 Promotes Cell Proliferation of Non-Small Cell Lung Cancer Cells: Involving in PTEN\/Akt\/Skp2 Signaling Pathway","volume":"36","author":"Bu","year":"2017","journal-title":"DNA Cell Biol."},{"key":"ref_31","first-page":"1949","article-title":"Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells","volume":"6","author":"Su","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.3892\/mmr.2016.5676","article-title":"Inhibiting the role of Skp2 suppresses cell proliferation and tumorigenesis of human gastric cancer cells via the upregulation of p27kip1","volume":"14","author":"Wen","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.ajpath.2011.01.050","article-title":"Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer","volume":"178","author":"Arbini","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_34","first-page":"501","article-title":"Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome","volume":"20","author":"Woenckhaus","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e8412","DOI":"10.1590\/1414-431x20198412","article-title":"Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis","volume":"52","author":"Yang","year":"2019","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_36","first-page":"451","article-title":"Inhibition of SKP2 Activity Impaired ATM-Mediated DNA Repair and Enhanced Sensitivity of Cisplatin-Resistant Mantle Cell Lymphoma Cells","volume":"34","author":"Yan","year":"2019","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.2147\/CMAR.S253367","article-title":"Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib","volume":"12","author":"Chen","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-019-0092-z","article-title":"USP10 modulates the SKP2\/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia","volume":"5","author":"Liao","year":"2019","journal-title":"Cell Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","article-title":"Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response","volume":"30","author":"Qin","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","author":"White","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_48","first-page":"85","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0014-4827(70)90362-9","article-title":"Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis","volume":"63","author":"Caspersson","year":"1970","journal-title":"Exp. Cell Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2018-99-113960","article-title":"PKM2 mediates chronic myeloid leukemia Imatinib resistance by regulating glycolysis energy metabolism","volume":"132","author":"Tong","year":"2018","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/bjc.2014.136","article-title":"Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells","volume":"110","author":"Yang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_54","first-page":"776","article-title":"FAM60A promotes cisplatin resistance in lung cancer cells by activating SKP2 expression. Anticancer","volume":"31","author":"Hou","year":"2020","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1038\/onc.2016.105","article-title":"OCT-4: A novel estrogen receptor--\u03b1 collaborator that promotes tamoxifen resistance in breast cancer cells","volume":"35","author":"Bhatt","year":"2016","journal-title":"Oncogene"},{"key":"ref_56","first-page":"1841","article-title":"S-phase kinase-associated protein 2 is involved in epithelialmesenchymal transition in methotrexate-resistant osteosarcoma cells","volume":"52","author":"Ding","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.1158\/0008-5472.CAN-08-1935","article-title":"Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.15430\/JCP.2020.25.4.252","article-title":"Imatinib and GNF-5 Exhibit an Inhibitory Effect on Growth of Hepatocellar Carcinoma Cells by Downregulating S-phase Kinase-associated Protein 2","volume":"25","author":"Zhang","year":"2020","journal-title":"J. Cancer Prev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3892\/ol.2020.11650","article-title":"Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol. Lett."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/6\/948\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:56Z","timestamp":1760138336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/6\/948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["genes13060948"],"URL":"https:\/\/doi.org\/10.3390\/genes13060948","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}